HomeBusinessThe smartest dividend stocks to buy now with $3,000

The smartest dividend stocks to buy now with $3,000

Need dividends? The stocks with the highest interest rates are not necessarily your best choice. Quality counts. A company must not only be able to continue to fund its payouts, but must also be able to grow its dividend payments in the future.

If you have a few thousand dollars and are ready to make new income-generating investments, here are three of the smartest dividend stocks on the market to buy now.

Start your morning smarter! Wake up with Breakfast news in your inbox every market day. Register for free »

There is no denying that the glory days of the pharmaceutical industry are in the past. This market has just become very crowded, both because of a number of similar drugs and a number of companies that make them. Merck (NYSE:MRK) is no exception.

What Merck may lack in raw growth power, it makes up for in smart portfolio management.

Take the best-selling drug Keytruda as an example. It’s on track to generate about $30 billion in revenue this year, up from nothing in 2013 when the oncology drug got its first approval (before several dozen more would be added). But Merck didn’t really develop it. It was acquired thanks to the 2009 acquisition of the biopharmaceutical company Organon, which came up with Keytruda’s winning formula in 2006, years before any approval and subsequent revenues. Previously, Merck’s breadwinner was arthritis treatment Remicade. Before that it was the successful asthma treatment Singulair, which was part of Schering-Plough’s portfolio when Merck bought it in 2009. Before Singulair, Merck’s flagship was the diabetes drug Januvia.

In this vein, even though Keytruda sales have never been stronger, the drugmaker has already made it a point to secure the development rights – at a bargain price, no less – to a cancer immunotherapy being developed by the Chinese LaNova Medicines and which only seems promising. a superior option to Keytruda.

The point is that Merck recognizes the inevitable end of the dominance of its best-selling drugs and is responding preemptively by next bestseller before it is a clear winner.

See also  Billionaire Ole Andreas Halvorsen has dumped Viking's entire stake in Broadcom in favor of a globally dominant company that has risen almost 2,400% since going public

Merck’s track record of updating its drug portfolio with the right drugs early and often is a key reason the company has now been able to increase its dividend for fourteen years in a row. And more than a little. The quarterly payout per share of $0.44 ten years ago is now $0.77. That’s an annualized growth rate of almost 6%, which easily exceeds inflation over the same period. Merck stock itself is also up more than 70% during this period, with a recent significant sell-off.

- Advertisement -
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Recent Comments